Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 25, 2020

View Archived Issues

Dosing completed in phase I study of ML-004 as therapy for social deficit in ASD

Making exceptional responders unexceptional

Twist reports preclinical data on antibodies against S1 protein in SARS-CoV-2

FDA approves Xofluza for post-exposure prophylaxis of influenza

Capricor initiates dosing in phase II study of CAP-1002 in severe COVID-19

Genmab halts development of enapotamab vedotin

CTA for first-in-human study of FS-222 receives clearance in Spain

Cure Biopharma patents gemcitabine prodrugs for cancer

Incyte discloses new CDK2/cyclin E inhibitors

Snap Bio presents new Pim-1 and/or Pim-3 kinase inhibitors

Merck & Co. describes new nicotinic alpha7 receptor PAMs

Humabs BioMed divulges antibodies targeting influenza A HA protein

Tremfya approved in E.U. for active psoriatic arthritis

Final phase I/II data for PLX-9486 plus sunitinib in GIST

First-in-human data presented for Plasmodium falciparum transmission-blocking MAb

shMKK4-224: an MKK4 inhibitor for liver regeneration

Initial first-in-human data on BMS-986218 support further evaluation

Antimicrobial polymers AMP up fight against MDR bacteria

Phase III interim data reported on Sputnik V COVID-19 vaccine candidate

Treating Zika virus in a pregnant nonhuman primate model

Topline phase IIa data on vibegron in IBS show primary endpoint not met

FDA approves Oxlumo for primary hyperoxaluria type 1

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...